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Abstract
Background: The present protocol was designed for a systematic review and meta-analysis aimed at determining
the association of telomere length with substance use disorders with the exclusion of nicotine addiction, and to
identify potential moderators of the effect of telomere length. Such methodological information may provide
guidance to improve the quality of future research on this important topic.
Methods: Potential studies will be identified through electronic databases (PubMed/MEDLINE, EMBASE, PsycINFO,
and Web of Science) up from inception onwards. The inclusion criteria will include published or unpublished
observational studies (cohort, case–control, and cross-sectional studies) reporting telomere length in adult patients
with substance use disorder compared with a control group. Non-human studies or other study designs such as
reviews, case-only, family-based, and/or population studies with only healthy participants will be excluded, as well
as those focused solely on nicotine addiction. The main outcome will be telomere length in adults with substance
use disorder (primary) and, specifically, in those with alcohol use disorder (secondary). Two investigators will
independently evaluate the preselected studies for possible inclusion and will extract data following a standardized
protocol. Disagreements will be resolved by consensus. The risk of bias of all included studies will be assessed using
the Newcastle–Ottawa Quality Assessment Scale for non-randomized studies. Data will be converted into standardized
mean differences as effect size index, and random-effects models will be used for the meta-analysis. Cochran’s Q
statistic, I2 index, and visual inspection of the forest plot will be used to verify study heterogeneity. Subgroup analyses
and meta-regressions will be conducted to ascertain heterogeneity. Several sensitivity analyses will be conducted to
address the influence of potential confounding factors. Publication bias will be examined using the “funnel plot”
method with Duval and Tweedie’s trim-and-fill method and Egger test.
Discussion: This systematic review will assess the association of telomere length with substance use disorders aside
from nicotine addiction.
Systematic review registration: PROSPERO registration number CRD42019119785
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Background
Human telomeres are repetitive noncoding DNA protein
structures consisting of nucleotide sequences of tandem
TTAGGG repeats at the end of chromosomes and asso-
ciated protective proteins essential for maintaining gen-
ome stability [1, 2]. Telomere length is the result of the
balance between telomere repeat additions and losses
and is known to become shorter as a function of in-
creased turnover and chronological age [3]. When telo-
mere length becomes critically short, cell proliferation
decreases and cell senescence ensues which has led telo-
mere length to be considered as a marker of cellular
aging [4–6]. Importantly, telomere length has been
shown to be affected by genetic, epigenetic, and other
non-genetic factors including exposure to stress and to
socioeconomic or lifestyle-related factors [2, 7].
During the past decade, telomere attrition has been as-
sociated with increased morbidity and mortality of dif-
ferent age-related diseases, such as metabolic syndromes
[8], diabetes mellitus [9], hypertension [10], increased
risk of coronary heart disease [11, 12], and Alzheimer’s
disease [13]. Short telomeres have also been associated
with increased all-cause mortality risk in the general
population [14]. Lastly, healthy lifestyles, including
proper nutrition and higher levels of physical exercise,
have been proposed to have protective effects on telo-
mere length [15, 16].
Recently, there has been growing interest regarding
the association of telomere length with known risk fac-
tors for mental illness including exposure to perceived
stress [17], chronic social stress [18], and childhood ad-
versities [19]. The association with mental disorders has
also received particular attention [20, 21]. In recent
meta-analyses, telomere length has been shown to be as-
sociated with depression [22, 23], bipolar disorder [24],
post-traumatic stress disorder [19], anxiety [25], Alzhei-
mer’s disease [13], schizophrenia [26, 27], and other psy-
chiatric disorders (with the specific exclusion of
substance use disorders (SUD)) [28]. The interest in
studying telomere length lies not only in its potential as
a biomarker for premature mortality or quality of life
[20], but also in personalized medicine with implications
for prognosis, treatment selection, and treatment re-
sponse to lifestyle interventions [29], pharmacotherapy
[20, 30–33], or psychotherapy [34].
To the best of our knowledge, only one meta-analysis
has examined the association between substance use dis-
orders and telomere length and has solely focused on
cigarette smoking [35]. The results suggested a shorter
telomere length among smokers compared with non-
smokers with an inverse dose–response relationship with
pack-years of smoking. Several empirical studies have
been published on the relationship between telomere
length and other SUDs, such as alcohol [36–38], cocaine
[39], and other drugs [40, 41]. A recent non-systematic
review has shown the inconsistency of the published re-
sults regarding the association between alcohol con-
sumption and telomere length [42]. We are not aware of
any systematic review or meta-analysis examining the as-
sociation of telomere length with any other substance
despite the extent and public health importance of sub-
stance use disorders.
The aims of the present study are (i) to systematically
review the scientific literature on telomere length and
SUDs to determine whether persons with SUDs have
shorter telomere lengths compared with healthy con-
trols, (ii) to explore potential differential effects with re-
gard to diverse substances aside from nicotine, (iii) to
identify potential moderators of the telomere length ef-
fect, and (iv) to investigate factors associated with poten-
tial heterogeneity in findings. To this end, the proposed
systematic review will answer the following questions: (i)
Do people with substance use disorders have shorter
telomere lengths compared with healthy controls? (ii)
Are there differences among substance users based on
the type of substance that is misused? (iii) if heterogen-
eity is confirmed and substantive and methodological
factors implicated in this heterogeneity. In particular, we
will investigate the potential association of individual
sociodemographic characteristics of the participants with
the effect sizes. In addition, the potential confounding
effects on the effect sizes will be investigated by analyz-
ing the influence of methodological characteristics of the
studies on the effect sizes, such as the design type and
risk of bias items.
Methods and analysis
The study protocol was reported according to the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocol (PRISMA-P) 2015 statement
[43] (see Additional file 1) and was registered prospect-
ively (PROSPERO 2019 CRD42019119785, http://www.
crd.york.ac.uk/PROSPERO).
Searches
We will search PubMed/MEDLINE, EMBASE, Psy-
cINFO, and Web of Science (from inception onwards)
using the following search terms for SUDs: “drug, sub-
stance, addiction, alcohol*, heroin, cocaine, opium, opi-
oid, methamphetamine, morphine” and for telomeres:
telomeres, telomerase, and telo*” (see a draft search in
Additional file 2). This search strategy was designed and
will be carried out by a librarian expert (ARV). The ref-
erence lists of original studies included in this initial se-
lection and review articles will then be manually
searched to identify other potentially eligible studies. In
addition, e-mails will be sent to the corresponding au-
thors of selected studies in an attempt to identify
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potential unpublished studies that fulfill our selection
criteria. To minimize potential publication bias, both
published and unpublished papers will be eligible for in-
clusion and no restrictions are placed on time period,
sample size, ethnicity, or language of publication.
Eligibility Criteria
Studies will be selected according to the following cri-
teria: (i) study design, (ii) participants, (iii) comparator,
and (iv) outcome(s) of interest. (i) Study design: We will
include observational studies (e.g., cohort, case–control,
and cross-sectional studies) reporting telomere length in
persons with SUDs compared with a control group (e.g.,
without SUDs). We will exclude studies in animals, ex-
perimental studies, reviews, case reports, case series,
studies conducted in healthy populations, and/or fam-
ilies. (ii) Participants: We will include adults with SUD
(regardless of age or sex) assessed by clinical interviews
or established standard diagnostic instruments including,
but not limited to, the Structured Clinical Interview for
DSM-IV (SCID), Computerized National Institute of
Mental Health Diagnostic Interview Schedule (CDISIV),
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) criteria, or Composite International Diagnos-
tic Interview (CIDI). We will exclude participants who
exclusively meet the criteria for nicotine addiction. (iii)
Comparator (or control group): The comparator group
will be based on subjects with no history of SUDs (e.g.,
the general population, the community, unexposed out-
patient, or hospital-based controls). (iv) Outcome(s):
The outcome of interest will be telomere length.
Selection and data collection
The results of the search strategy in the different data-
bases will be combined in a unique file and duplicates
and non-human research will be removed. Two investi-
gators will independently review the title and abstract of
each study identified through the search strategy to de-
termine eligibility for inclusion. Full articles will be re-
trieved from the Internet or via library access when
possible or by contacting corresponding authors when
necessary. Data from each study will then be extracted
independently using a previously defined protocol de-
signed for data extraction and entered into two separate
databases. In case of disagreement of study inclusion or
in data extraction, a consensus will be reached with the
involvement of the other researchers.
The following data will be extracted from each study:
(i) author(s), journal, language, and year of publication;
(ii) methods (study design, sample sizes for both cases
and controls, diagnostic tools for the determination of
case status, definition of case status and adjusted ana-
lyses, attrition for cases and controls and differential at-
trition); (iii) risk of bias assessment (described in greater
detail below); (iv) sample characteristics for both cases
and controls separately (gender ratio, mean age and
standard deviation (SD), ethnic background, education
level, type of substance use in cases, duration of sub-
stance use disorder in cases, presence of other mental
disorders or medical illness, smoking status, exposure to
childhood adversities and other stressful life events, and
if the latest or any other variable has been measured be-
fore the onset of SUD in cases); and (v) telomere-related
information (telomere length, tissue source, and telo-
mere measurement method). The purpose of extracting
all of these characteristics is to have the opportunity of
examining their association with the effect sizes.
If additional groups of persons suffering from other
psychiatric diagnoses are described in a study, only data
from the substance use disorders sample and the control
group will be extracted. The unit of analysis will be stud-
ies (rather than reports) to ensure data are not counted
twice. As a result, in cases of multiple articles stemming
from a single study, only the results of the publication
with the highest number of participants will be included.
If an article reports on two or more studies with inde-
pendent samples, then each independent study will be
included as an analysis unit in the meta-analysis. If es-
sential data are missing from the study reports, the au-
thors of the respective papers will be contacted and
asked to provide additional data.
Risk of bias (quality) assessment
The risk of bias of each study selected for inclusion will
be assessed using the Newcastle–Ottawa Scale (NOS)
for non-randomized studies in meta-analyses [44].
Studies will not be weighted by the overall quality
score, and those with low values will not be excluded a
priori. Discrepancies in the quality assessment of each
study will be resolved by consensus. The influence on
the effect size of each item assessed will be individually
assessed [45].
Strategy for data synthesis
Statistical analysis
For each study, the data will be converted into standard-
ized mean differences (SMDs) as effect size index. The
SMD is calculated as the mean difference in telomere
length between the SUD (MSUD) and control (MControl)
groups divided by the pooled standard deviation of the
two groups (S): SMD = c(m)(MSUD – MControl)/S, with
c(m) being a correction factor for small sample sizes de-
fined as c(m) = 1 − 3/(4N – 9), N being the sum of the
two sample sizes [46]. If means and standard deviations
are not reported in the study, formulas will be applied to
obtain the SMD from other statistical data (e.g., t tests, F
tests, p values, correlations, odds ratios, etc.) [47]. Nega-
tive SMDs will represent a shorter telomere length for
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the SUD group compared with the control group. For
each SMD, a 95% confidence interval (95% CI) will be
calculated. In this meta-analysis, unadjusted effect sizes
(SMDs) will be used. The potential influence of con-
founding factors will be assessed as described below.
Because a high level of heterogeneity is expected,
random-effects models will be used a priori for SUD
overall and for each independent substance consumed if
the number of available studies allows it. Random-effects
modeling assumes a genuine diversity in the results of
the various studies and incorporates between-studies
variance into the calculations. Random-effects models
imply to weight each effect size by its inverse variance,
this being the sum of the within-study and the between-
studies variance. The between-studies variance will be
estimated by restricted maximum likelihood [47]. Aver-
age effect size and a 95% CI will then be calculated with
the improved method proposed by Hartung and Knapp
[48–50]. Instead of assuming a standard normal distribu-
tion, the method by Hartung and Knapp assumes a Stu-
dent t distribution with k – 1 degrees of freedom (k
being the number of studies) and an improved estimator
of the variance of SMD that takes into account the un-
certainty in estimating the between-studies variance. In
addition, a 95% prediction interval around the average
effect size will be calculated, in order to provide a pre-
diction of the expected true effects if a new study is con-
ducted [47, 50].
To estimate heterogeneity between studies, the
Cochran`s Q statistic, the I2 index, and visual inspection
of the forest plots will be used. Q statistic is a weighted
sum of the squared of the deviations of individual effect
estimates from the overall estimate. A statistically signifi-
cant result for the Q statistic is indicative of heterogeneity.
The I2 index is calculated as I2 = 100(Q − df)/Q, with df
being the degrees of freedom of the Q statistic: df = k – 1
(k being the number of studies). I2 is interpreted as the
percentage of total variation across studies due to hetero-
geneity. The I2 index takes values between 0 and 100%
with higher values denoting a greater degree of heterogen-
eity (0–25%: no or negligible heterogeneity; 25–50%: mod-
erate heterogeneity; 50–75%: large heterogeneity; and 75–
100%: extreme heterogeneity). I2 values of 25% or more
will lead to investigate the influence of moderator vari-
ables. In addition, heterogeneity will be assessed with the
between-studies variance and 95% confidence interval. Fi-
nally, following Mathur and VanderWeele’s (2019) pro-
posal, the estimated proportion (and 95% confidence
interval) of true effect sizes exceeding a scientifically
meaningful threshold will be calculated. In terms of stan-
dardized mean difference, we will consider − 0.20 the
threshold effect size for these calculations [51].
In cases of moderate-to-large heterogeneity (I2 > 25%),
we will seek to identify possible explanations using
subgroup analyses and meta-regressions based on the
most important characteristics of the studies, including
items used to evaluate the risk of bias. The analysis of
moderating variables will be accomplished by assuming
a mixed-effects model. Categorical moderators will be
analyzed by comparing the average effect size of each
category of the moderator [52], whereas continuous
moderators will be analyzed by means of meta-
regressions [53]. In both cases, the improved F statistic
developed by Knapp and Hartung will be applied for
testing the statistical significance of each moderator [54].
To estimate the proportion of variance accounted for by
the moderator, an R2 index will be calculated [55].
Research on telomere length for persons with SUD must
dedicate special attention to the potential influence of
confounding factors. In order to address this point, several
sensitivity analyses will be conducted. First, the risk of bias
items of the NOS will be analyzed by means of subgroup
analyses. Second, the comparability of the groups (cases
and controls) is a key issue to assess the potential influ-
ence of confounding factors on effect sizes, with age being
the most relevant confounding factor. In addition, to apply
subgroup analyses to the risk of bias item on comparabil-
ity of the NOS, simple meta-regressions will also be con-
ducted using the SMDs as a dependent variable and the
mean difference in age between cases and controls, the
difference in age SDs, the difference in the proportion of
males and of Caucasians, and the difference in education
levels. Third, another set of subgroup analyses will be con-
ducted with other covariates related to telomere length,
such as smoking status, exposure to childhood adversities
or other stressful events, and the presence of mental or
physical comorbidities.
The presence of publication bias will be examined using
the “funnel plot” method using Duval and Tweedie’s trim-
and-fill method [56], the Egger test [57], and the
precision-effect test–precision-effect estimate with stand-
ard error (PET-PEESE) method [58]. A sensitivity analysis
will then be performed to assess whether our results were
substantially influenced by the presence of any individual
study by systematically removing each study and recalcu-
lating the significance of the overall results. If conditions
impede meta-analysis, data will be narratively presented.
All statistical analyses will be conducted using the metafor
program in R [59]. To judge the quality of evidence for all
outcomes, the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach will be
used [60]. Results will be reported according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [61].
Discussion
To the best of our knowledge, this systematic review and
meta-analysis will be the first to systematically assess the
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association of telomere length with any other substance
despite the extent and public health importance of sub-
stance use disorders. The results of this systematic re-
view should be interpreted with caution as there are
some potential limitations at the study and review level.
At the study level, (i) the study design of the original
studies might limit causal relation as cross-sectional and
case–control designs are expected to be found, rather
than longitudinal studies, and (ii) a high level of hetero-
geneity in the quality of the designs is expected. At the
review level, (i) the analyses of this meta-analysis will be
based on unadjusted estimates as different adjustments
by different potential confounders are expected in ori-
ginal studies. The potential impact of those moderating
variables (age, gender, tobacco smoking, among others)
will be assessed by a combination of subgroup and
meta-regression analyses; (ii) differences in the tissue
types and methods used to measure telomere length is
expected; and (iii) the scarcity of studies may limit some
subgroup or stratified analyses individual substances.
This review will provide information on potential
moderators of the telomere length effect related to an
expected heterogeneity in published scientific literature.
The assessment of risk of bias (or “quality”) of individual
studies included and how the results might influence the
review findings will be useful for researchers in future
projects.
No ethical issues are anticipated. The results of this
systematic review and meta-analysis will be published in
a peer-reviewed journal or conference presentation.
Should any amendment be introduced in the present
protocol, a description of the changes and their rationale
with the date of incorporation will be updated in the
PROSPERO register and be acknowledged in the publi-
cation of the results.
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